<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01099124</url>
  </required_header>
  <id_info>
    <org_study_id>TMU-CIH-CTI-001</org_study_id>
    <nct_id>NCT01099124</nct_id>
  </id_info>
  <brief_title>Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Single-center, Open Trail of Phase 1 of M2ES With TC Regimen in Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and tolerance of M2ES with TC regimen in
      advanced NSCLC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events incidence,including severe adverse events incidence</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate and disease controlled rate</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>M2ES combined with chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2ES</intervention_name>
    <description>polyethylene glycol rh recombinant endostatin</description>
    <arm_group_label>M2ES combined with chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-70 years old;

          2. Patients with Ⅲ/Ⅳ NSCLC confirmed by histopathology or cytology who ware naive or
             previous chemotherapy without TC regimen;

          3. No contraindication for chemotherapy;

          4. ECOG performance scale 0-2;

          5. No history of anti-angiogenesis therapy;

          6. Patients are voluntary to participate and sigh the informed contents.

        Exclusion Criteria:

          1. Concurrent use of other anti-cancer agents;

          2. Allergic history to M2ES and biological agents;

          3. Pregnant or breast-feeding women;

          4. With other malignancy;

          5. With severe cardiopulmonary disease;

          6. Uncontrolled brain metastasis patients;

          7. Other conditions that are regarded for exclusion by the trialists.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai LI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institude and Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institude and Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>April 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2010</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>M2ES</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Phase I Trial</keyword>
  <keyword>Advanced NSCLC</keyword>
  <keyword>Recurrent NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

